[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention: GP1681Administration: oral (liquid formulation)Multiple Ascending Dose (MAD) studyCohort 1: GP1681 5mcg every 8 hours for 7 days (6 active; 2 placebo)Cohort 2: GP1681 TBC mcg every 8 hours for 7 days (6 active; 2 placebo)Cohort 3: GP1681 TBC mcg every 8 hours for 7 days (6 active; 2 placebo)Each cohort will be evaluated for safety by a Dose Escalation Committee (DEC) before escalation to the next dose level cohort. Based on this review; the DEC will decide on the dose level for the next cohort. The next cohort will start 2 weeks after the previous cohort. Dose escalation will begin at 15 mcg/day and continue until either a maximum tolerated dose (MTD) or a maximum dose of 90 mcg/day is reached or until 3 cohorts have been enrolled.To monitor any responses and adherence to the intervention; GP1681 will be administered under direct supervision.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "Cohort 1: GP1681 5mcg every 8 hours for 7 days (6 active, 2 placebo)", "treatment_id": 552, "treatment_name": "Gp1681", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Cohort 2: GP1681 TBC mcg every 8 hours for 7 days (6 active, 2 placebo)", "treatment_id": 552, "treatment_name": "Gp1681", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Cohort 3: GP1681 TBC mcg every 8 hours for 7 days (6 active, 2 placebo)", "treatment_id": 552, "treatment_name": "Gp1681", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]